Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
David P. Dearnaley(Royal Marsden NHS Foundation Trust), Alan Horwich(Institute of Cancer Research)
Cited by 230
Related Papers
Multiple newly identified loci associated with prostate cancer susceptibility
|Nature Genetics|2008|850
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2010|600
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
|Annals of Oncology|2019|182
Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer
|British Journal of Cancer|2002|16
The ESMO guideline strategy: an identity statement and reflections on improvement
|Annals of Oncology|2015|5